Loading clinical trials...
Loading clinical trials...
This is a 3 month open-label extension study that allows patients who completed Protocol MNTX 302 to receive SC MNTX.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Bausch Health Americas, Inc.
NCT06615349 · Terminal Illness, Terminal Cancer
NCT07477028 · Terminal Illness, End-of-Life Care, and more
NCT06793631 · People with Terminal Illness
NCT06628856 · Terminal Illness
NCT04678310 · Terminal Illness
Progenics Pharmaceuticals, Inc.
Tarrytown, New York
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions